DDInter1631 DDInter210
Safinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.
Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with the BRAF V600E or V600K mutations, as detected by an FDA-approved test.
Binimetinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Delavirdine
Binimetinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Troleandomycin
Binimetinib {u} may lead to a major life threatening interaction when taken with {v} Ramucirumab
Binimetinib {u} may lead to a major life threatening interaction when taken with {v} Zanubrutinib
Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Delavirdine
Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin
Binimetinib may lead to a major life threatening interaction when taken with Ramucirumab
Binimetinib may lead to a major life threatening interaction when taken with Zanubrutinib